OAB0603 | Changes in body mass index over time in persons with and without HIV | Oral abstract session with live Q&A | B22 |
OAB0602 | Weight gain and hyperglycemia during the dolutegravir transition in Africa | Oral abstract session with live Q&A | B21 |
OAB0507 | TB contact investigations as an active HIV case finding strategy in Mozambique: Lessons for high TB and HIV syndemic countries | Oral abstract session with live Q&A | B10 |
OAB0506 | Validation of a laboratory-based reference test for TB-LAM and FLOW-TB, a novel point-of-care TB diagnostic assay, in a high-HIV-prevalence clinical cohort from KwaZulu-Natal, South Africa | Oral abstract session with live Q&A | B10 |
OAB0505 | Risk factors for hepatotoxicity in HIV-infected women receiving isoniazid preventive therapy in pregnancy and postpartum | Oral abstract session with live Q&A | B10 |
OAB0504 | Assessment of the tuberculosis clinical cascade among children living with HIV on antiretroviral therapy, 16 Sub-Saharan PEPFAR-supported programs, October 1, 2018 to March 31, 2019 | Oral abstract session with live Q&A | B10 |
OAB0503 | Prevalence and incidence of tuberculosis infection and disease among household contacts exposed to rifampin-resistant/multidrug resistant tuberculosis (RR/MDR-TB) | Oral abstract session with live Q&A | B10 |
OAB0502 | Efficacy and safety outcomes (HIV subgroup analysis) in the Nix-TB Trial - bedaquiline, pretomanid and linezolid for treatment of extensively resistant, intolerant or non-responsive pulmonary multidrug-resistant tuberculosis | Oral abstract session with live Q&A | B10 |
OAB0405 | Sub-optimal outcomes with switching to zidovudine vs. recycling tenofovir in second-line treatment in Haiti | Oral abstract session with live Q&A | B30 |
OAB0404 | Third-line antiretroviral therapy including raltegravir, darunavir/ritonavir and/or etravirine is well tolerated and achieves durable virologic suppression over 144+ weeks in resource limited settings ACTG: A5288 strategy trial | Oral abstract session with live Q&A | B31 |